| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Cell-penetrating peptide (CPP); Furin (serine endoprotease) inhibitor; neuroprotective agent.
|
|---|---|
| ln Vitro |
(Arg)9 (Nona-L-arginine; 5-10 μM) significantly reduced the effects of glutamate exposure in a dose-response fashion (IC50=0.78 μM). After being exposed to kainic acid, (Arg)9 exhibited neuroprotective properties, however not as much as the glutamate model (IC50=0.81 μM). Additionally, (Arg)9 (IC50=6 μM) has neuroprotective effects following ischemia in vitro [1].
(Arg)9 is a cell-penetrating peptide composed of 9 arginine residues and is an inhibitor of serine endoprotease Furin. It exhibits neuroprotective activity with an IC50 of 0.78 μM in a glutamic acid-induced model. Poly-arginine-9 (R9) is 17-fold more neuroprotective than TAT in a cortical neuronal glutamate excitotoxicity model. It requires heparan sulfate proteoglycan-mediated endocytosis to induce neuroprotective effects. |
| ln Vivo |
In the male Sprague-Dawley rat persistent middle cerebral artery stroke model, (Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); intravenous injection; once for 30 minutes) has neuroprotective effects and reduces infarct volume [2].
(Arg)9 exhibits neuroprotective effects in vivo when administered intravenously after stroke onset in a rat model. It has been shown to reduce glutamic acid-induced neuronal calcium influx and provide neuroprotection in stroke models. The peptide is used for delivery of therapeutic cargo in vivo. |
| Enzyme Assay |
(Arg)9 is not amenable to conventional enzymatic or receptor binding assays. Its cell-penetrating activity is assessed by conjugating the peptide to a fluorescent cargo and measuring cellular uptake by flow cytometry or fluorescence microscopy. Internalization efficiency is quantified as the percentage of fluorescent cells.
|
| Cell Assay |
In cellular assays, primary cortical neuronal cultures are treated with (Arg)9 and subjected to glutamic acid excitotoxicity, kainic acid, or oxygen-glucose deprivation (OGD) injury. Cell viability is measured using MTT or LDH release assays. Neuroprotection is quantified by comparing treated and untreated cultures.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (270 to 320 g) permanent middle cerebral artery stroke model [2]
Doses: 1 μM/kg (600 μL) Route of Administration: intravenous (iv) (iv)injection; intravenous (iv) (iv)injection; intravenous (iv) (iv)injection. One time, over 5 minutes. Experimental Results: Significant 20% reduction in infarct volume. In vivo studies use rat models of stroke (permanent middle cerebral artery occlusion). (Arg)9 is administered intravenously after stroke onset, and infarct volume and neurological outcomes are assessed. The peptide's neuroprotective efficacy is evaluated by comparing treated and control groups. |
| References |
|
| Additional Infomation |
Arginine is being studied in the clinical trial NCT00264706 (Polyarginine-treated intravenous transplantation (patent)).
|
| Molecular Formula |
C54H110N36O10
|
|---|---|
| Molecular Weight |
1423.6864
|
| Exact Mass |
1422.92
|
| CAS # |
143413-47-2
|
| Related CAS # |
(Arg)9 acetate;(Arg)9 TFA;2283335-13-5
|
| PubChem CID |
25077438
|
| Sequence |
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-ArgRRRRRRRRR
|
| SequenceShortening |
RRRRRRRRR
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.192
|
| tPSA |
853.22
|
| Hydrogen Bond Donor Count |
28
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
53
|
| Heavy Atom Count |
100
|
| Complexity |
2850
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[R][R][R][R][R][R][R][R][R]
|
| InChi Key |
XUNKPNYCNUKOAU-VXJRNSOOSA-N
|
| InChi Code |
InChI=1S/C54H110N36O10/c55-28(10-1-19-74-46(56)57)37(91)83-29(11-2-20-75-47(58)59)38(92)84-30(12-3-21-76-48(60)61)39(93)85-31(13-4-22-77-49(62)63)40(94)86-32(14-5-23-78-50(64)65)41(95)87-33(15-6-24-79-51(66)67)42(96)88-34(16-7-25-80-52(68)69)43(97)89-35(17-8-26-81-53(70)71)44(98)90-36(45(99)100)18-9-27-82-54(72)73/h28-36H,1-27,55H2,(H,83,91)(H,84,92)(H,85,93)(H,86,94)(H,87,95)(H,88,96)(H,89,97)(H,90,98)(H,99,100)(H4,56,57,74)(H4,58,59,75)(H4,60,61,76)(H4,62,63,77)(H4,64,65,78)(H4,66,67,79)(H4,68,69,80)(H4,70,71,81)(H4,72,73,82)/t28-,29-,30-,31-,32-,33-,34-,35-,36-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7024 mL | 3.5120 mL | 7.0240 mL | |
| 5 mM | 0.1405 mL | 0.7024 mL | 1.4048 mL | |
| 10 mM | 0.0702 mL | 0.3512 mL | 0.7024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.